Zymeworks, global biotechnology company, shared a post on X:
“We are thrilled to be sharing new clinical data from our first-in-human multicenter open-label study of our folate receptor α (FRα)–targeting antibody-drug conjugate (ADC).
Abstract CT306, will be held Tuesday, April 21, 2026 at 2:30 – 4:30 pm Pacific Standard Time (PST).
Presenter: Dr. Patricia LoRusso
We hope to see you there! Learn more about our AACR presentations. ”
Other articles about Zymeworks on OncoDaily.